You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

KORLYM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Korlym, and what generic alternatives are available?

Korlym is a drug marketed by Corcept Therap and is included in one NDA. There are eighteen patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-nine patent family members in twelve countries.

The generic ingredient in KORLYM is mifepristone. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mifepristone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Korlym

A generic version of KORLYM was approved as mifepristone by GENBIOPRO on April 11th, 2019.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for KORLYM?
  • What are the global sales for KORLYM?
  • What is Average Wholesale Price for KORLYM?
Summary for KORLYM
Drug patent expirations by year for KORLYM
Recent Clinical Trials for KORLYM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Corcept TherapeuticsPhase 4
Charles Drew University of Medicine and SciencePhase 2
National Institute on Alcohol Abuse and Alcoholism (NIAAA)N/A

See all KORLYM clinical trials

Pharmacology for KORLYM
Paragraph IV (Patent) Challenges for KORLYM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
KORLYM Tablets mifepristone 300 mg 202107 1 2017-12-15

US Patents and Regulatory Information for KORLYM

KORLYM is protected by eighteen US patents.

Patents protecting KORLYM

Method for differentially diagnosing ACTH-dependent cushing's syndrome
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Optimizing mifepristone levels for Cushing's patients
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Optimizing mifepristone levels for cushing'S patients
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Method for differentially diagnosing ACTH-dependent Cushing's syndrome
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Optimizing mifepristone absorption
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Optimizing mifepristone levels for cushing's patients
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Optimizing mifepristone absorption
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Method for differentially diagnosing ACTH-dependent Cushing's syndrome
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Optimizing mifepristone levels for cushing's patients
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING CUSHING'S SYNDROME

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for KORLYM

See the table below for patents covering KORLYM around the world.

Country Patent Number Title Estimated Expiration
Israel 269009 טיפול משולב בו זמנית עם מודולטורים של קולטני גלוקוקורטיקואידים ומעכבי cyp3a (Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors) ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2018160775 ⤷  Sign Up
Japan 2019503495 異所性クッシング症候群の鑑別診断 ⤷  Sign Up
Japan 2023052618 糖質コルチコイド受容体モジュレータおよびCYP3Aインヒビタの併用投与 ⤷  Sign Up
South Korea 20180052120 ACTH-의존성 쿠싱 증후군을 감별 진단하는 방법 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.